Applied UV, Inc. (NASDAQ:AUVI) Q4 2022 Earnings Call Transcript

Applied UV, Inc. (NASDAQ:AUVI) Q4 2022 Earnings Call Transcript April 3, 2023

Operator: Greetings, and welcome to the Applied UV Fourth Quarter and Year End 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode and a question-and-answer session will follow the formal presentation. Please note, this conference is being recorded. I will now turn the conference over to your host, Brett Maas of Hayden IR. You may begin.

Brett Maas: Thank you. Once again, welcome to Applied UV’s 2022 earnings call. With me today on the call are Max Munn, Founder and CEO, President and Director; Mike Riccio, Chief Financial Officer; and Brian Stern, President of Puro Lighting. As a reminder, all materials for today’s live presentation are available on the company’s Investor Relations website at applieduv.com. Sorry, let’s say it again, applieduvinc.com. Before we begin, please take a moment to read the forward-looking statements in our earnings press release. During today’s call, we will make certain predictive statements that reflect our current views about future performance and financial results. We base these statements in certain assumptions and expectations on future events that are subject to risks and uncertainties.

Our most recent Form 10-K lists some of the most important risk factors that could cause actual results to differ from our predictions. With that, I will turn the call over to Max Munn. Max, the floor is yours.

Max Munn: Thank you, Brett, and good morning, everyone. My name is Max Munn, I’m the Founder of Applied UV. And I became the CEO about three weeks ago. As it was for most other companies, 2022 was a very challenging year. Our challenge arose from the acquisition of Scientific Air in late 2021. With disinfection products that were substantially focused on one distributor, Scientific Air was also focused on one industry, which was hospitals and with revenues totally driven by COVID-19. Consequently, sales collapsed for Scientific Air in 2022 as the pandemic receded. Unfortunately, our previous senior management’s focus did not reposition the company to address this weakness at Scientific Air. Consequently, we recently determined that it was best to write down a substantial portion of our investment in Scientific Air and put this problem behind us.

In addition to this non cash write down of goodwill, the company has incurred and our 2022 financials include significant onetime integration and acquisition costs related to this legal and accounting expenses associated with our more successful acquisitions included in our 2022 expenses or other noncash items, such as depreciation, interest and the issuance of options to key employees. 2022 was indeed a very challenging year, but it was also a turnaround year. We are therefore starting 2023 with our company much better positioned to achieve significantly improved results. Of this, I am extremely optimistic. As a reminder, Applied UV has two operating segments, the pathogen elimination and disinfection segment, which includes the development, manufacture and marketing of air and surface disinfecting systems.

And the Hospitality segment, which includes domestic manufacturer of better mirrors and premium furniture specifically for hotels, resorts and related properties. Now I’d like to take a more detailed review of our Hospitality segment. In Hospitality, MunnWorks is resuming its pre pandemic growth as this industry continues to show strong growth fueled by the post pandemic travel surge, which has accelerated faster than generally forecasted. This market growth has heightened the need for hotels to make capital improvements to facilities in order to maintain their franchise flex, something that was postponed for almost three years due to the pandemic. Hotel operators are now required to catch-up on delayed refurbishment. In the last few months, we had several hotel developers place multimillion dollar orders with our company.

This surging demand coupled with our newly acquired 100,000 square foot manufacturing facility located in Brooklyn, New York has given us a strong competitive advantage due to the demand for domestic manufacturing by these hotel operators. The cost differential between China and domestic manufacturing has decreased considerably due to the 25% tariff, as well as other factors leading hotel management to favor U.S. based manufacturing. Additionally, there is a significant fear of potentially higher tariffs because hotel developers are concerned with the ongoing negative dialogue between the U.S. and China, worrying that any potential conflict or even a threat of a conflict could result in more global supply chain disruptions, as well as incremental and increased tariffs.

These factors are driving more hotel operators to domestic manufacturing to mitigate supply chain delays and enable hotels to better manage project timelines and ultimately their revenue generation. Due to the shift and with very limited U.S. competition, we were able to raise prices significantly without displacing orders, which will result in margin expansion, which we expect to accelerate in the first half of 2023. As part of the Brooklyn facility acquisition we inherited, a number of lower margin products due to the fact that 50% deposits were paid in advance of our acquisition of the facility, but paid to prior owners of that business, leaving us with fulfilling those major hotel commitments without the benefit of the associated cash receipts.

We delivered on those commitments and all of our legacy orders have now been fulfilled. Our sales pipeline for Hospitality, which is approximately $10 million today with projects underway and slated in Cleveland, Washington DC, Indianapolis, Orlando and Knoxville. We also plan to increase MunnWorks revenues through the installation of our pathogen elimination devices as an option into our hotel guest room furniture to be supplied to better hotels. Now let me discuss the pathogen elimination and disinfection segment of our business. The domestic UV disinfection market is expected to reach $9 billion in 2027. The (ph) states that each year one in 25 patients gets a hospital acquired infection resulting in over 3 million serious infections and 100,000 deaths annually.

This amounts to losses from contagious pathogens that cost the U.S. economy more than $270 billion, including lost productivity due to absenteeism. The recent CDC warning about the rapid spread of new and deadly drug resistant super books such as , coupled with the urgency for improvements in indoor air quality within HVAC systems. In order to control the spread of pathogens we will continue to drive adoption of many of our proven systems. Our recent acquisition of Puro and its technology further validates our long term strategy for developing or acquiring the best technology to protect all of us from deadly pathogens. This strategy is not only correct, but is now firmly in place. Our technology helps keep people safe, but just as important our technology protects and extends the shelf life of high value agricultural products.

With shortages and purchase restrictions, the resulting food insecurity being reported throughout the world, we have concluded that protecting food from farm to table is a high priority and a major opportunity for us. Currently, with 15% to 25% of shipped agricultural products lost to spoilage during transit, to distribution centers and transfer to food retailers, our company in a venture with Canon Virginia, a unit of the Japanese company will soon introduce a proprietary air purification system that can be incorporated into shipping containers and long haul refrigeration trucks, as well as distribution centers that we expect will significantly reduce food spoilage. This technology is the same photo catalytic oxidation system, which we developed for NASA for use in the International Space Station.

Our technology is not only currently being used to increase the shelf life for food, but we are already generating revenue in the cannabis industry and in wine storage and we also expect to expand into the preservation of cut flowers during transit and display. We believe that our focus on food security is as urgent as has healthcare and is also one of the highest investment priorities in the world today. We plan on growing our revenues in post-harvest food security by leveraging our success with our Airocide product line, because we have already demonstrated the reduction of food spoilage of high value fruit and berries with global companies such as Del Monte, , Whole Foods and others. Two months ago, we completed the acquisition of Puro Lighting as well as LED supply.

As a result, we are forecasting total revenues of approximately $45 million to $50 million for this current year, approximately 100% increase over 2022. This further positions Applied UV as a fully integrated company providing a broad pathogen elimination platform with leading technology that can be used by consumers, business and governments. At this point, I want to also reiterate that I personally agree with the recent projection by a major investment banking research analyst that our common share price will likely reach $2.50 by the end of this current year. Our primary focus for growth in 2023 will be on food preservation, healthcare and safe building systems and will include the complete installation utilizing proprietary software and facilities HVAC systems, which will continually monitor indoor air quality.

With the merger of Puro complete, our wholly owned subsidiary, SteriLumen is gaining critical mass to address the ever challenging and ever changing challenge of combating air and surface pathogens at hospitals for required infections protecting businesses and their facilities and their employees and consumers who frequent the facilities. After long delays due to the COVID pandemic, late in 2022, our company began a clinical trial with our Lumicide sink and drain disinfection product at the prestigious Mt Sinai Hospital in New York City. We expect to announce the results of this highly anticipated clinical trial in Q3 2023. To support our planned growth, we formed a scientific advisory board with renowned infectious disease scientists, as well as wine and food preservation experts.

The company plans to have these experts speak at leading industry conferences and trade shows, as well as write publications in leading journals regarding the effectiveness of our pathogen elimination product. We plan to announce the details regarding this advisory board in the very near term. Our global distribution and strategic partnership expansion continued throughout 2022 with the company now boasting several established strategic manufacturing partnerships and alliances. With Canon, Acuity Lighting, Johnson Controls, USHIO, Siemens and Granger. Additionally, our pathogen elimination segment’s global network has grown to include 89 dealers and distributors in 52 countries, including Southeast Asia, with 47 sales agencies as well as our having 19 U.S. based sales personnel.

Photo by National Cancer Institute on Unsplash

Our global customers will now have access to our complete suite of research backed and clinically proven best-in-class product, including photo catalytic oxidation, advanced UVC activated carbon, far UV technology utilizing newly developed 222 nanometer wavelength radiation, as well as our new air monitoring and reporting software for use in smart building products. We recently announced a significant strategic manufacturing supply chain outsourcing agreement with Canon Virginia, a wholly owned subsidiary of Canon USA, one of the premier global advanced contract manufacturers. This agreement makes Canon the company’s primary manufacturer and logistical partner for our entire suite of air purification solutions. Our joint teams continue executing on an accelerating plan to completely transfer our manufacturing to Canon during this current quarter.

We will simultaneously close our existing manufacturing and distribution operations, yielding a significant reduction in our fixed G&A. We believe this partnership will translate into production and logistics cost savings that accelerate development of our next generation product by removing manufacturing execution risk and allowing the company to more effectively scale and focus on advanced technology development and marketing. We’ve also recently expanded our relationship with Canon Japan to include Canon Financial Services as a partner, which allows our company to offer for the first time leasing and finance options for our product to our customers. With the Puro acquisition, we’re obtaining PURONet software application, which will further differentiate our systems from those of our competitors.

Through the introduction of PURONet proprietary systems, our software will accelerate our industry differentiation by adding IoT integration throughout our entire product portfolio with proven software that continually monitors and reports indoor air quality throughout an entire facility. PURONet has recently been installed into almost 100 surgical suites. Puro’s HVAC system products allows us to competitively compete in one of the fastest growing air pathogen elimination markets, offering complete systems with our proprietary air monitoring software, which is rapidly becoming a must have in HVA systems. To conclude, 2023 will be a transformative and extremely positive year for AUVI. Now, I would like to turn the call over to Brian Stern, President of Puro Lighting, allowing him to speak more about Puro and LED supply.

Brian?

Brian Stern: Thank you, Max. This is Brian Stern. I was the CEO and Co-Founder of both LED Supply Co and Puro Lighting. My new role as President of Puro Lighting and Board Director allows me to consolidate, integrate and create a uniformed vision for our air and surface disinfection technologies, which are made up of Airocide, Acientific Air, Lumicide and Puro Lighting. At Puro, our goal is to use this merger to leverage cross selling opportunities and increase revenue per customer, while also improving bottom line profitability for the division and the organization as a whole. I’m proud to share that LED Supply Co., which I co-founded 14 years ago has greatly expanded its business and we now provide design services, lighting and technology distribution, OEM product development, after sales service and turnkey installations for new construction, renovation and national account projects across the United States.

Our reach is also expanded from just lighting and controls to include building technologies such as EV chargers, building automation systems, UV devices and smart panels for low voltage irrigation gas and water metering. Our customers range from large developers to national energy service contractors, as well as lighting and electrical service providers. The merger with Applied UV allows us to realize many synergies with our LED Supply Co business. We’re already enjoying the benefits of the merger as we have been able to start specifying MunnWorks mirrors and case goods products on a multitude of different projects. This has enabled us to provide our customers with a higher quality product with a better price point and improved gross margins for the company.

And we recently announced a major $4.5 million contract with (ph), the country’s premier co living rental property developer that has over $1 billion in planned construction. Moving on to Puro Lighting, which was founded in 2019 with a mission of using light technologies to improve health and wellness within buildings. Today, Puro Lighting has an offering that encompasses pathogen elimination and disinfection of HVAC systems, induced air applications, continuous air disinfection technologies and surface disinfection technologies which are primarily sold into healthcare, education, commercial facilities and government spaces. We expect to announce in the very near future that we have renewed our agreement with one of the leading distributors of hospitals, expanding our reach into healthcare with our PURONet systems which utilize far UV technology.

with this agreement, we also expect to announce that our PURONet disinfection control systems are scheduled to be installed in 16 operating rooms at a leading medical school. This renewed agreement should help Applied UV achieve greater penetration of the PURONet systems within the hospital segment, serviced by this distributor. Hospitals currently utilizing the PURONet system include Mass General, University of Chicago Med and Children’s Nursing in Kansas City. Puro has continued to expand our business partnerships with the newly announced research partnership with Johnson Controls and USHIO. This partnership allows us to provide additional research on the safety and efficacy of far UV technologies. Additionally, we announced an expanded partnership with Acuity Brands to further expand our Puro far UV portfolio of products.

Next, I will turn the call over to Mike Riccio, our Chief Financial Officer, for a review of our financial results. Mike?

Mike Riccio: Thanks, Brian. Net sales of $2.01 million represented an increase of $8.5 million or 73% for the year ended December 31, 2022 as compared to net sales of $11.6 million for the prior year. This improvement was primarily attributable to the Hospitality segment with sales of $13.6 million, representing an increase of $7.7 million or 130% as compared to the prior year. This was largely due to the VisionMark asset acquisition in Brooklyn, accounting for $6 million of the increase, plus the increase in sales in the legacy MunnWorks business of $1.7 million. The pathogen elimination and disinfection segment had sales of $6.5 million in 2022, which represented a 14% increase over the prior year. The pathogen eliminations and disinfection markets have not yet fully rebounded from the initial buy in during the early stages of the COVID pandemic.

Additionally, due to macro market shifts, the company saw major global trends toward end-to-end systems across entire facilities, that includes software monitoring capabilities. This allows facilities to implement standards in the current EPA clean the air initiatives and guidelines announced in early 2022. These guidelines set the standards that are focused on improving indoor air quality, including indoor air ventilation and HVAC systems in all public places. With these shifting macro trends, the company altered its marketing, M&A and R&D activities to address these changes. The Puro merger, coupled with the strategic manufacturing partnership with Canon further addresses this shift. Gross profit was $4.0 million, which is approximately 20% of sales the year ended December 31, 2022, as compared to $4.1 million or approximately 35% of sales for the prior year.

Gross profit as a percentage of sales decreased primarily due to the higher sales mix of the Hospitality segment. The Hospitality segment sales for the year ended December 31, 2022 were 68% of AUVI’s total as compared to 51% for the prior year. Additionally, the Hospitality segment’s gross profit as a percentage of sales decreased year-over-year largely due to the completion of projects that were in process when the company first acquired the assets of VisionMark in Brooklyn, which is a nonrecurring condition. The company is totally focused on streamlining both manufacturing and distribution operations across both segments. SG&A costs were $14.8 million for the year ended December 31, 2022, which represented an increase of $3.5 million as compared to the prior year.

This increase was primarily driven by the asset acquisitions of VisionMark in Brooklyn in the Hospitality segment in Q1 2022 and the asset acquisitions of KES Science and Technology and Scientific Air in the pathogen elimination and disinfection segment at the end of Q3 and the beginning of Q4 in 2021. As a result, payroll and sales commission costs increased approximately $1.5 million, amortization costs increased approximately $1 million, marketing increased approximately $0.4 million and rent and professional fees, each increased approximately $0.5 million. The company anticipates efficiency gains in the coming year as all three acquisitions have now been fully integrated and synergies are being realized. The company had determined that a triggering event had occurred as a result of a settlement agreement with Scientific Air.

A quantitative impairment test on the goodwill determined at the fair value was below the carrying value. And as a result, the company recorded a full non cash goodwill impairment charge of $1.1 million on the consolidated statements of operations for the year ended December 31, 2022. We also evaluate a potential triggering events that might be indicators that other intangibles related to Scientific Air were also impaired. As a result of our analysis, an additional non cash impairment of intangibles of $5.9 million was also recorded in the consolidated statements of operations for the year ended December 31, 2022. As a result of the Scientific Air settlement and the change in the values of the shares of stock returned to the company, the company recorded a net gain of $1.4 million in other income in the year ended December 31, 2022.

Other income in the year ended December 31, 2022 also includes $205,000 for the employee retention tax credit. The company recorded a net loss of $16.6 million for the year ended December 31, 2022 compared to a net loss of $7.4 million for the prior year. This increase of $9.2 million in the net loss was primarily due to the noncash loss on impairment of goodwill and intangibles of $7.0 million and an increase in SG&A cost of $3.5 million as previously explained. The loss per share — per common share is $1.41 for 2022. If we exclude the impairment loss, the loss per common share is $0.86, as compared to $0.86 — a loss of $0.86 in 2021, which is in line with the guidance given by a prominent investment banking research analyst. With the integration of the Puro merger rapidly progressing, coupled with the shifting of our entire supply chain, logistics, offshore manufacturing and next generation product R&D to Canon, the savings and the reduction of duplicated expenses across all of our divisions is expected to equate through improvements in our SG&A, driving higher future earnings.

Lastly, I would like to talk about the company’s efforts to strengthen the liquidity. On July 1, 2022, the company filed a $50 million shelf registration on Form S-3, which — with the SEC which allows for flexibility to raise funds as needed. Additionally, in December 2022, the company entered into a loan and security agreement with Pinnacle Bank, which provides for a $5 million secured revolving credit facility. At December 31, 2022, the company had approximately $2.7 million of unrestricted cash available on its consolidated balance sheet. I will now turn the call back over to Max for closing remarks.

Max Munn: Well, thank you. Let me just say that as the founder of Applied UV and recently taking on the row as the CEO I’m absolutely committed to our success. 2022 was a tough year for all of us, but it was also a transformative year. We will continue to focus on our strategic priorities while at the same time tightening expenses across all of our businesses, aligning our resources including cash with current demand. I’m extremely optimistic about the outlook for both of our pathogen elimination and hospitality segments. We now have a great portfolio of highly effective product that management — our management team and I truly believe will be strong leavers for growth in 2023. Thank you again everyone for joining our call today. This concludes our prepared remarks. The operator can now open the call for questions.

See also 11 Most Promising Gene Editing Stocks and 11 Most Promising Clean Energy Stocks.

Q&A Session

Operator: Thank you. At this time we will be conducting a question-and-answer session. Our first question is coming from Chip Moore with EF Hutton. You may proceed.

Chip Moore: Good morning. Thanks. Hey, everybody. First, I guess, on visibility comfort around that $45 million to $50 million top line goal. I think Max, I heard you talk about sort of a near term pipeline of $10 million for MunnWorks, VisionMark. Any other sense of pipeline for Puro, LED and some of the other parts of the business?

Max Munn: Well, Brian, Stern, why don’t you respond to the pipeline for Puro and LED? And then I can talk a bit more about why we’re very comfortable about a $45 million to $50 million a year?

Brian Stern: Sure. So current pipelines for Puro and LED, Puro currently has roughly a $500,000 million pipeline as of the end of the last quarter. And LED roughly a $4.5 million pipeline with strong sales expectations for the remainder of the year for both organizations. So we feel very confident in the numbers that are being portrayed. And hopefully we’ll be able to meet those goals this year.

Max Munn: Chip, the backlog between all of our businesses is in excess of $15 million at the end of the first quarter last week. We know what the outlook is in the near term because we’re quoting a significant number of jobs and the percentage of conversion of quotes to actual orders to actual receipts gives us a great deal of comfort that we will hit that $45 million to $50 million and will — we — there’s even a reasonable expectation that we’ll exceed that. We have a great expectation that there are several very large multimillion dollar projects that we’ve been working on throughout 2022 that we will get actual POs for this current quarter. So I’m — the metrics, the backlog, the RFQs that we’re dealing with give us that comfort. I hope I’ve answered your question.

Chip Moore: No, that’s very helpful, Max. I appreciate it. And I guess around Hospitality, specifically I guess capacity there with Brooklyn and then I think you talked about getting through those lower margin orders. How should we think about that margin ramp for Hospitality? I guess specifically over the next few quarters throughout the year.

Max Munn: Prior to the pandemic, MunnWorks was running at margins in excess of — in the low to mid-30s, we expect to be back to those margin levels. Now that we’ve completed the projects that were undertaken during the acquisition of the Brooklyn facility, which as I explained, 50% of the proceeds were turned over to the prior owners which we didn’t enjoy. So the margins are — I think are pretty much established historically. But I will tell you, the problem on it will have if we’re going to exceed the forecast is a labor shortage and we’re working diligently with New York City agencies to train at their expense employees as much of this country has already experienced getting decent employees with some skills is really the challenge today.

It isn’t the facility, it isn’t the $9 million worth of equipment that we acquired with this facility. It’s really employees. We’re on over time right now working on several large projects. We’re just about to receive a $3 million to $4 million order from a European hotel developer for a major hotel refurbishment and rebranding in Washington DC. So the challenge is going to be labor. Not machinery, not the facility, not raw materials, it’s a problem that is solvable, but it is an issue to deal — in response to your question about where our capacity constraints are.